A235980 Stock Overview
A drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MedPacto, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,675.00 |
| 52 Week High | ₩17,240.00 |
| 52 Week Low | ₩4,420.00 |
| Beta | 0.72 |
| 11 Month Change | -25.56% |
| 3 Month Change | -33.78% |
| 1 Year Change | -37.67% |
| 33 Year Change | -91.68% |
| 5 Year Change | n/a |
| Change since IPO | -73.96% |
Recent News & Updates
Companies Like MedPacto (KOSDAQ:235980) Are In A Position To Invest In Growth
Nov 18
Companies Like MedPacto (KOSDAQ:235980) Are In A Position To Invest In Growth
Aug 05MedPacto (KOSDAQ:235980) Is In A Good Position To Deliver On Growth Plans
Mar 28Recent updates
Companies Like MedPacto (KOSDAQ:235980) Are In A Position To Invest In Growth
Nov 18Companies Like MedPacto (KOSDAQ:235980) Are In A Position To Invest In Growth
Aug 05MedPacto (KOSDAQ:235980) Is In A Good Position To Deliver On Growth Plans
Mar 28We Think MedPacto (KOSDAQ:235980) Can Afford To Drive Business Growth
Jan 05Shareholder Returns
| A235980 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -2.2% | -5.8% | -2.8% |
| 1Y | -37.7% | 28.2% | -3.4% |
Return vs Industry: A235980 underperformed the KR Biotechs industry which returned 28.2% over the past year.
Return vs Market: A235980 underperformed the KR Market which returned -3.4% over the past year.
Price Volatility
| A235980 volatility | |
|---|---|
| A235980 Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A235980 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A235980's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 57 | Seong-Jin Kim | www.medpacto.com |
MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea.
MedPacto, Inc. Fundamentals Summary
| A235980 fundamental statistics | |
|---|---|
| Market cap | ₩156.99b |
| Earnings (TTM) | -₩27.75b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.7x
P/E RatioIs A235980 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A235980 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩27.75b |
| Earnings | -₩27.75b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -826.40 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did A235980 perform over the long term?
See historical performance and comparison